We have developed a proprietary human tissue engineering system that mimics physiological aspect of inflammation.
Using bio-imaging, we can measure:
Recruitment movement of leukocytes through blood vessel wall
Retention Blockade of leukocytes egress from inflammatory tissue
We can access clinical sample to explore processes in:
Chronic disease modeling
MesenFlow Technologies has developed a platform to meet the demands of modern drug development. It is a bio-imaging technology designed to accelerate the drug development process & provide solutions to problems associated with species cross-reactivity, animal testing & understanding human disease. This has been achieved by using proprietary protocols on primary human cells, allowing the mechanism of action & translational relevance of a drug to be defined very early on in the development process.
MesenFlow Technologies has recently extended this technology for use in cosmetics and nutrition. By using our technology, it is possible to explore the physiological impact of a cosmetic or nutraceutical candidate in the early development phase. Our services are particularly tailored to business environments where animal-free testing is mandatory, and an understanding of impact on human biology is paramount.
Riccardo Nisato, PhD MBA
General Manager, Elanix SA,
CSO, Genes-X SA
Director, Stemedica SA
Paul Bradfield, PhD MBA
20+ Years R&D in translational medicine
Project Leader, MerkSerono SA
20+ Publications, patents
Professor Beat Imhof PhD
Ex-President of ESM & SSAI
Ex-Chair – Department of Pathology & Immunology, University of Geneva
180+ publications, patents
+41 22 32 16 961 (office)
+41 79 36 66 291 (mobile)